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Abstract
Background and Objective Almorexant is the first rep-
resentative of the new class of orexin receptor antagonists,
which could become a new treatment option for insomnia.
The present study investigated the potential interaction
between almorexant and warfarin.
Methods In this open-label, two-way crossover, drug–
drug interaction study, healthy male subjects received, in a
randomized fashion, almorexant 200 mg once daily for
10 days and a single dose of 25 mg warfarin co-adminis-
tered on day 5 (treatment A) and a single dose of 25 mg
warfarin on day 1 (treatment B). Serial blood samples for
warfarin pharmacokinetics and pharmacodynamics were
drawn during both treatments.
Results Of the 14 enrolled subjects, one withdrew due to
an adverse event and 13 completed the study. Almorexant
had no effect on the pharmacokinetics of warfarin. The
geometric mean ratios (90 % confidence interval) for the
area under the plasma concentration–time curve to infinity
(AUC0–?) of S- and R-warfarin were 0.99 (0.89, 1.09) and
1.05 (0.95, 1.16), respectively, and for the maximum
plasma concentration (Cmax) were 0.99 (0.86, 1.14) and
1.00 (0.88, 1.13), respectively. The main pharmacody-
namic variable was the AUC for the international nor-
malized ratio (AUCINR). Almorexant had no effect on this
variable as demonstrated by a geometric mean ratio of 0.99
(0.82, 1.19). Secondary pharmacodynamic variables
including maximum effect (Emax), the time to the maxi-
mum INR, and factor VII plasma concentrations were also
not affected by almorexant.
Conclusion No dose adjustment of warfarin is necessary
when concomitantly administered with almorexant.
1 Introduction
The orexin or hypocretin system was discovered in 1998,
and a number of experimental observations have suggested
that this system plays an important role in the sleep–wake
cycle [1–5]. These observations have spurred considerable
interest in the development of orexin receptor antagonists
as a potential new treatment for insomnia [6, 7]. Almo-
rexant is the first representative of this new class of com-
pounds, which has shown promising sleep-promoting
activity in animals, healthy subjects, and patients with
primary insomnia [8–10].
The pharmacokinetics of almorexant after single- and
multiple-dose administration to healthy subjects have been
described previously [9, 11, 12]. In brief, they are char-
acterized by a clearance of 43 L/h, a large volume of dis-
tribution (683 L), a fast absorption (time to Cmax [tmax]
*1 h), and a rapid disposition due to a pronounced dis-
tribution phase, with concentrations decreasing to less than
20 % of maximum plasma concentration (Cmax) 8 h after
administration. Following multiple-dose administration,
steady-state concentrations were reached after 4–5 days of
dosing, and accumulation was minimal. In vitro, almo-
rexant has been shown to be an inhibitor (inhibitory con-
stant approximately 2 lM) of cytochrome P450 (CYP)
isoenzymes CYP2C9, CYP2D6, and CYP3A4 but not of
other CYP isoenzymes (Actelion Pharmaceuticals, data on
file). For this reason, a drug–drug interaction study was
performed in healthy subjects investigating the effect of
almorexant on midazolam and simvastatin, two model
substrates of CYP3A4 [13]. This study showed that
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almorexant only marginally increased exposure to midaz-
olam, but exposure to simvastatin and its hydroxyacid
metabolite was increased by 3.4- and 2.8-fold, respectively
[14]. The difference in sensitivity of both CYP3A4 sub-
strates is consistent with the observation that in vitro
almorexant inhibited testosterone 6b-hydroxylation but not
midazolam 10-hydroxylation (Actelion Pharmaceuticals,
data on file).
The anticoagulant warfarin acts by inhibiting the
regeneration of vitamin K1 epoxide, which is necessary for
the post-ribosomal synthesis of vitamin K-dependent clot-
ting factors such as factors II, VII, IX, and X. Warfarin is
administered as a racemic mixture of S- and R-enantio-
mers. Its elimination is almost entirely by metabolism
followed by urinary excretion of metabolites with minimal
anticoagulation activity [15]. Warfarin is metabolized by
CYP isoenzymes to inactive hydroxylated metabolites and
by reductases to reduced metabolites. The S-enantiomer is
primarily metabolized by CYP2C9 and less by CYP2C19
and CYP3A4, whereas the R-enantiomer is mainly
metabolized by CYP1A2 with a smaller contribution of
CYP3A4 [16]. Warfarin has a narrow therapeutic index,
and small changes in its pharmacokinetics may lead to the
need for dose adaptation.
The present study investigated further the drug–drug
interaction potential of almorexant by studying its effects




This was a single-center, open-label, randomized, two-way
crossover, drug–drug interaction study. Screening of sub-
jects took place between 21 and 3 days before first study
drug administration. Enrolled subjects were randomized to
treatment sequences A/B or B/A. Treatment A consisted of
almorexant 200 mg once daily on day 1–10 and a single
dose of 25 mg warfarin co-administered on day 5; treat-
ment B consisted of a single dose of 25 mg warfarin on day
1. A 2-week washout period between treatments was
respected. A dose of 200 mg almorexant was chosen
because it was expected to be well tolerated and it was the
highest dose investigated in phase III trials. Study drugs
were administered in the morning to subjects in the fasted
state, with breakfast served 2 h thereafter. During both
treatments, subjects were confined to the study center from
approximately 12 h prior to warfarin administration until
144 h thereafter. Because of the sleep-promoting properties
of almorexant, subjects stayed in the clinic under super-
vision for approximately 5 h after its intake on days 1–4 of
treatment A. After this 5-h observation period, a physician
determined whether the subject was fully alert and could be
allowed to go home or whether there were any residual
effects that could be attributed to a sleep-promoting drug
(e.g., muscular weakness, dizziness, fatigue, or somno-
lence). Subjects were not to drive a car or engage in
activities that required operating vehicles or dangerous
machinery. From screening until the end-of-study exami-
nation, which was performed 144 h after warfarin admin-
istration in the second treatment period, subjects had to
refrain from excessive physical exercise and strenuous
sports activities and were not allowed to consume cran-
berries, grapefruit, cranberry juice, or grapefruit juice.
Although no effect of grapefruit juice on the pharmaco-
dynamics of warfarin could be shown [17], cranberry juice
increased the international normalized ratio (INR) [18].
This study was conducted in full conformity with the
Declaration of Helsinki and its amendments. The protocol
was approved by an independent ethics committee (Ethics
Committee of the Medical University, Graz, Austria). Each
subject provided written informed consent prior to any
study procedure.
2.2 Inclusion and Exclusion Criteria
Eligible subjects were healthy males aged between 18 and
45 years who had a body mass index between 18 and
28 kg/m2 at screening. Subjects were judged to be healthy
based on medical history, physical examination, ECG, vital
signs, and clinical laboratory tests. Subjects were not
enrolled if they had a history of hemorrhagic disease, fre-
quent nasal, hemorrhoidal, or gingival bleeding, an acti-
vated partial thromboplastin time [40 s, an INR [1.15, a
low (\150 9 109) or high ([400 9 109) platelet count, or
had been treated with any medication (including over-the-
counter and herbal medicines) within 2 weeks prior to
screening.
2.3 Blood Sampling and Bioanalytical Methods
Blood samples for the determination of S- and R-warfarin
were collected in tubes with ethylenediaminetetra-acetic
acid (EDTA) as anticoagulant at the following time points:
pre-dose, and 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 96, 120, and
144 h following the warfarin dose during both treatment
periods. The tubes with blood were centrifuged, the plasma
separated, and all plasma samples were stored in an upright
position at -20 C pending analysis. The stereoselective
bioanalysis of warfarin in plasma was done using a vali-
dated high pressure liquid chromatography (HPLC) cou-
pled to tandem mass spectrometry (MS/MS) method. In
brief, 300 lL of acetonitrile containing internal standards
(deuterated S- and R-warfarin) was added to 100 lL of
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plasma. Following protein precipitation and centrifugation,
15 lL of the supernatant was injected onto the HPLC
system. The latter consisted of a C18 pre-column (5 lm,
4 9 3.0 mm; Phenomenex, Aschaffenburg, Germany), a
Reprosil Chiral-NR analytical column (8 lm,
125 9 3.0 mm; Dr. Maisch GmbH, Ammerbruch, Ger-
many), a Waters Alliance 2795 pump, degasser, and
autosampler (Waters, Eschborn, Germany). The columns
were eluted with a mixture of methanol:5 mM ammonium
acetate pH 4.0 (70:30 v/v) for 11 min. The MS/MS analysis
(Quattro LC, Micromass, Wythenshawe, UK) was per-
formed in the positive ionization mode, and the limit of
detection was 20 ng/mL for both analytes. For R-warfarin,
the inter-day coefficients of variation (imprecision) were
B11.0 %, whereas inter-day inaccuracy ranged between -
1.1 and 0.6 %. For S-warfarin, imprecision was B10.1 %,
whereas inter-day inaccuracy ranged between -2.0 and -
0.4 %.
Blood samples for the determination of factor VII and
INR were collected pre-dose, and 4, 8, 12, 24, 36, 48, 60,
72, 96, 120, and 144 h after dosing with warfarin during
both treatment periods in tubes containing citrate as anti-
coagulant. These samples were put on ice and sent as soon
as possible to the local clinical laboratory for analysis. The
assay of factor VII was performed by a standard one-stage
method on fresh plasma. The results are expressed in per-
cent of the laboratory reference value. The prothrombin
time of each sample was measured using a standard test
and then standardized to yield the INR, a fraction that has
no unit. In treatment A, blood samples for determination of
trough almorexant plasma concentrations were collected
pre-dose on days 1–10 and 24 h after the last almorexant
dose on day 10 in tubes with EDTA as anticoagulant.
Concentrations in plasma were measured using a validated
LC–MS/MS assay with a lower limit of quantification of
0.05 ng/mL and imprecision and inaccuracy B4.9 and
5.3 %, respectively [14].
2.4 Pharmacokinetic and Pharmacodynamic Analyses
Pharmacokinetic and pharmacodynamic variables were
determined by non-compartmental analysis using Win-
Nonlin Professional Version 5.2.1 (Pharsight Corporation,
Mountain View, CA, USA). The Cmax or maximum effect
(Emax) and corresponding time point (tmax or tEmax ) were
directly obtained from the plasma concentration- or effect-
time profiles. The area under the plasma concentration–
time curve (AUC) from time 0 to time t of the last mea-
surable concentration (AUC0–t) was calculated using the
linear trapezoidal rule. The AUC from time 0 to infinity
(AUC0–?) was calculated by AUC0–t ? Ct/kz, where Ct is
the last measurable concentration and kz the terminal
elimination rate constant determined by log-linear
regression analysis of the measured plasma concentrations
in the terminal elimination phase. The elimination half-life
(t) of S- and R-warfarin was calculated as follows:
t = 0.693/kz. For both INR and factor VII, the AUC was
calculated for the period 0–144 h and absolute values are
reported.
2.5 Statistical Analysis
The null hypothesis was that one of the 90 % confidence
limits (two-sided based on t-distribution) of treatment A
versus treatment B for at least one of the five primary
pharmacokinetic and pharmacodynamic endpoints (Cmax
and AUC0–? for S- and R-warfarin and AUCINR) was
outside the interval 0.8–1.25. The type-I error was set to
0.05 and the power to 90 %. A sample size of 12 provided
more than 95 % power to reject the null hypothesis
assuming a standard deviation of the difference (in log
scale) equal to 0.13 [19].
Treatment differences are displayed using the ratio of
the geometric means (treatment A/treatment B) with their
corresponding 90 % confidence limits for Cmax, AUC0–?,
and AUCINR derived from a mixed model analysis of
variance with treatment and subject considered fixed
effects. The 90 % two-sided confidence limits of the geo-
metric mean ratio were derived using the antilog of the
90 % confidence limits of the difference of the mean
between treatment A and treatment B (on the natural log-
arithmic scale) and were evaluated using the t-distribution.
As the null hypothesis of all five primary pharmacokinetic
and pharmacodynamic endpoints should have been rejected
in order to demonstrate bioequivalence between the two
treatments, no correction for multiple testing was needed.
3 Results
3.1 Study Subjects
In this study, 14 healthy male subjects were randomized,
and their mean (range) values for age and body mass index
were 29.0 (21–44) years and 24.9 (22.9–28.1) kg/m2.
Except for one Black subject, all were White/Caucasian.
Thirteen subjects completed the study and were included in
the per-protocol analysis set. One subject prematurely
withdrew from the study in period 1 due to nausea after
having received the first dose of almorexant.
3.2 Pharmacokinetics
The mean plasma concentration–time profiles of S- and
R-warfarin alone and during concomitant administration
of almorexant are superimposable (Fig. 1). The
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pharmacokinetics of S- and R-warfarin were similar in the
absence and presence of almorexant and characterized by a
median tmax of 2.0 h, Cmax values of about 1,200 ng/mL
and values for t of about 39 h (S-warfarin) and 50 h (R-
warfarin) (Table 1).
Results of the statistical analysis confirmed the absence
of a pharmacokinetic interaction between warfarin and
almorexant (Table 2). The geometric mean ratios and
corresponding 90 % confidence intervals were entirely
within the bioequivalence limits of 0.80–1.25 for the
variables Cmax and AUC0–? of S- and R-warfarin. No
period or sequence effects were observed.
Mean trough plasma concentrations of almorexant
showed that steady-state concentrations had been attained
by day 4 (mean ± SD, 5.0 ± 2.2 ng/mL) and that the
concomitant warfarin dose on day 5 had no effect on the
trough plasma concentration of almorexant.
3.3 Pharmacodynamics
A dose of 25 mg warfarin caused an increase in INR that
was similar in the absence and presence of almorexant. The
maximum increase in INR was observed 24 h after
administration, and INR had returned to baseline 144 h after
administration (Fig. 2). Derived pharmacodynamic vari-
ables of INR did not differ between treatments (Table 3),
and the statistical analysis showed that the geometric mean
ratio and its 90 % confidence limits for AUCINR were
within the limits of 0.80–1.25. No bleeding adverse events
were reported during the study (data not shown).
Following administration of warfarin, both in the
absence and presence of almorexant, factor VII concentra-
tions decreased (Fig. 3). The maximum decrease occurred
24–36 h after administration, and factor VII slowly returned
to baseline thereafter. The pharmacodynamic analysis
appeared to show a difference in the time to Emax between
treatments, i.e., 36 h for treatment A and 24 h for treatment
B, whereas other variables were similar (Table 3).
4 Discussion
Almorexant is a dual orexin receptor antagonist and has
been shown in vitro to inhibit CYP2C9, CYP2D6, and


















































Fig. 1 Arithmetic mean (and standard deviation) plasma concentra-
tion–time profile of S-warfarin (top panel) and R-warfarin (bottom
panel) after administration of a single dose of 25 mg warfarin alone
(treatment B) and in the presence of almorexant 200 mg once daily
for 10 days with a single dose of 25 mg warfarin on day 5 (treatment
A) to healthy male subjects (n = 13)
Table 1 Pharmacokinetic variables of S- and R-warfarin after single-dose administration of 25 mg warfarin to healthy male subjects in the
presence (treatment A) and absence (treatment B) of almorexant (n = 13)
Treatment Cmax (ng/mL) tmax (h) AUC0–t (ng/mL 9 h) AUC0–? (ng/mL 9 h) t (h)
S-warfarin
A 1,200 (1,082, 1,331) 2.0 (1.0–4.0) 41,931 (35,062, 50,147) 45,726 (37,122, 56,324) 39.3 (32.7, 47.2)
B 1,211 (1,058, 1,386) 2.0 (1.0–4.0) 42,666 (34,634, 52,561) 46,325 (36,729, 58,249) 38.7 (32.1, 46.7)
R-warfarin
A 1,196 (1,082, 1,320) 2.0 (1.0–4.0) 62,913 (56,879, 69,586) 73,612 (64,766, 83,667) 52.4 (46.6, 58.9)
B 1,199 (1,055, 1,362) 2.0 (1.0–12) 61,354 (54,131, 69,541) 70,045 (61,280, 80,065) 48.6 (43.8, 53.8)
Data are geometric means (and 95 % confidence limits) or, for tmax, the median (and range)
AUC area under the plasma concentration–time curve, Cmax maximum plasma concentration, tmax time to Cmax, t elimination half-life
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CYP3A4 (Actelion Pharmaceuticals, data on file). The
present study investigated the effects of almorexant on
warfarin pharmacokinetics and pharmacodynamics in a
randomized, two-way crossover study. Such a design
reduces variability as each subject serves as his own con-
trol, thereby reducing the number of subjects to be included
and is in accordance with current guidelines for in vivo
interaction studies [20]. Warfarin was administered when
almorexant concentrations were in steady state and any
possible inhibition of CYP isoenzymes was maintained
during the elimination phase of warfarin by continued
administration of almorexant.
The pharmacokinetics of warfarin in the absence of
almorexant were in good agreement with previously
reported results [19, 21]. Almorexant was not expected to
influence the pharmacokinetics of R-warfarin as this
compound is mainly metabolized by CYP1A2 [16], an
enzyme that is not inhibited by almorexant. However,
almorexant also did not exert any effect on S-warfarin
pharmacokinetics. Previously, almorexant had been shown
to increase exposure to simvastatin, a CYP3A4 substrate, in
healthy subjects [14], whereas in vitro it is a more potent
inhibitor of CYP2C9, the major metabolizing enzyme of
S-warfarin. The inhibition constants of almorexant for
CYP2C9 and CYP3A4 (marker: testosterone 6b-hydrox-
ylation) inhibition were 1.6 and 2.9 lM, respectively
(Actelion Pharmaceuticals Ltd, data on file). The expla-
nation for these findings lies in the fact that CYP2C9, in
contrast to CYP3A4, is not expressed in the gastrointestinal
system. Our previous experiments [14, 22] made it plau-
sible that the CYP3A4 inhibitory properties of almorexant
are mainly expressed at the gastrointestinal rather than the
Table 2 Geometric mean ratios (treatment A/treatment B) and 90 %
confidence limits of the primary pharmacokinetic and pharmacody-
namic variables of warfarin (n = 13)
Variable Geometric mean ratio
(90 % confidence limits)
Cmax of S-warfarin 0.99 (0.86, 1.14)
AUC0–? of S-warfarin 0.99 (0.89, 1.09)
Cmax of R-warfarin 1.00 (0.88, 1.13)
AUC0–? of R-warfarin 1.05 (0.95, 1.16)
AUCINR 0.99 (0.82, 1.19)
AUC area under the plasma concentration–time curve, Cmax maxi-
mum plasma concentration, INR international normalized ratio
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Fig. 2 Arithmetic mean (and standard deviation) international nor-
malized ratio (INR) versus time profile after administration of a single
dose of 25 mg warfarin alone (treatment B) and in the presence of
almorexant 200 mg once daily for 10 days with a single dose of
25 mg warfarin on day 5 (treatment A) to healthy male subjects
(n = 13)
Table 3 Pharmacodynamic variables of international normalized
ratio and factor VII after single-dose administration of 25 mg war-
farin to healthy male subjects in the presence (treatment A) and
absence (treatment B) of almorexant (n = 13)
Variable Treatment A Treatment B
Baseline INR (fraction) 1.0 (1.0, 1.1) 1.0 (1.0, 1.1)
tEmax INR (h) 24.0 (8.0–36.0) 24.0 (4.0–36.0)
Emax INR (fraction) 1.7 (1.5, 1.9) 1.9 (1.6, 2.2)
AUCINR (fraction 9 h) 38.5 (30.1, 49.2) 38.8 (30.9, 48.8)
Baseline factor VII (%) 82.6 (70.7, 96.5) 86.9 (71.3, 106)
tEmax factor VII (h) 36.0 (24.0–36.0) 24.0 (24.0–36.0)
Emax factor VII (%) 16.1 (12.1, 21.4) 17.1 (12.7, 23.1)
AUCfactor VII (% 9 h) 3,368 (2,676, 4,241) 3,281 (2,226, 4,835)
Data are geometric means (and 95 % confidence limits) or, for tmax,
the median (and range)
AUC area under the plasma concentration–time curve, Emax maximum
effect, INR international normalized ratio
























Fig. 3 Arithmetic mean (and standard deviation) plasma concentra-
tion–time profile of factor VII after administration of a single dose of
25 mg warfarin alone (treatment B) and in the presence of almorexant
200 mg once daily for 10 days with a single dose of 25 mg warfarin
on day 5 (treatment A) to healthy male subjects (n = 13)
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hepatic level, also related to higher local concentrations.
This was delineated by time-separated administration of
almorexant and simvastatin [22]. The lack of an effect of
almorexant on the pharmacokinetics of S-warfarin is in
accordance with insufficient concentrations of almorexant
to inhibit CYP2C9. With a dose of 200 mg, a Cmax value of
93.2 ng/mL or 0.17 lM was observed after 4 days of
dosing [11], i.e., well below the inhibitory constant for
CYP2C9, particularly when considering free drug con-
centrations of almorexant. It should be mentioned, how-
ever, that plasma concentrations do not necessarily reflect
local concentrations in the liver.
In agreement with the lack of an effect on warfarin
pharmacokinetics, concomitant administration of almorex-
ant had no effect on the warfarin-induced increase in INR
and decrease in factor VII plasma concentrations. When-
ever possible, pharmacodynamic variables should be
included in drug–drug interaction studies even when no
pharmacokinetic interaction is expected as sometimes there
may be a disconnect between pharmacokinetics and phar-
macodynamics. For example, the intake of cranberry juice
enhanced the effect of warfarin on INR in healthy subjects
without affecting warfarin pharmacokinetics [18]. The
authors explained this observation by an increase in sensi-
tivity to warfarin induced by cranberry, especially in sub-
jects carrying variant genotypes of the vitamin K epoxide
reductase subunit 1 gene (VKORC1). No such increase in
sensitivity to warfarin was observed in the present study.
The blood sampling scheme applied in the present study
was optimized to investigate the pharmacokinetics of
warfarin and only few blood samples were taken around
the Emax of pharmacodynamic variables. This may very
well explain the observed increase in tEmax of factor VII in
the presence of almorexant when compared with warfarin
alone. For both treatments, the range of individual tEmax
values of factor VII was the same (24–36 h). However,
during treatment A, seven subjects had a tEmax of 36 h and
six subjects a tEmax of 24 h, whereas numbers were six and
seven subjects, respectively, for treatment B, resulting in
the observed difference in median tEmax .
5 Conclusion
Almorexant has no influence on the pharmacokinetics and
pharmacodynamics of warfarin. No dose adjustment of
warfarin is necessary when concomitantly administered
with almorexant.
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